Optimization and evaluation of surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry for protein profiling of cerebrospinal fluid

Proteome Science

Volumn 4, Issue , 2006, Pages

  Guerreiro, Nelson ^a   Gomez Mancilla, Baltazar ^a   Charmont, Stéphane ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CYANO 4 HYDROXYCINNAMIC ACID; PEPTIDE; PROTEIN; SINAPIC ACID;

ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HIGH THROUGHPUT SCREENING; HUMAN; INFORMATION PROCESSING; METHODOLOGY; MOLECULAR SIZE; PRINCIPAL COMPONENT ANALYSIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DENATURATION; PROTEIN DETERMINATION; PROTEIN MICROARRAY; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEOMICS; REPRODUCIBILITY; SIGNAL NOISE RATIO; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 33646821324     PISSN: 14775956     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-4-7     Document Type: Article

References (40)

1. Zheng W, Chodobski A: The Blood-Cerebrospinal Fluid Barrier. New York. Taylor & Francis; 2005.
2. Thompson EJ: Cerebrospinal Fluid: CSF Proteins and Their Relevance in Research, Diagnostics and Treatment. London: Elsevier Academic Press; 2004.
3. Davidsson P, Sjogren M: The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis Markers 2005, 21:81-92.
4. Rohiff C: Proteomics in neuropsychiatric disorders. Int J Neuropsychopharmacol 2001, 4:93-102.
5. Romeo MJ, Espina V, Lowenthal M, Espina BH, Petricoin EFIII, Liotta LA: CSF proteome: a protein repository for potential biomarker identification. Expert Rev Proteomics 2005, 2:57-70.
6. Siman R, McIntosh TK, Soltesz KM, Chen Z, Neumar RW, Roberts VL: Proteins released from degenerating neurons are surrogate markers for acute brain damage. Neurobiol Dis 2004, 16:311-320.
7. Lamerz J, Selle H, Scapozza L, Crameri R, Schulz-Knappe P, Mohring T, Kellmann M, Khamenia V, Zucht HD: Correlation-associated peptide networks of human cerebrospinal fluid. Proteomics 2005, 5:2789-2798.
8. Ramstrom M, Ivonin I, Johansson A, Askmark H, Markides KE, Zubarev R, Hakansson P, Aquilonius SM, Bergquist J: Cerebrospinal fluid protein patterns in neurodegenerative disease revealed by liquid chromatography-Fourier transform ion cyclotron resonance mass spectrometry. Proteomics 2004, 4:4010-4018.
9. Wenner BR, Lovell MA, Lynn BC: Proteomic analysis of human ventricular cerebrospinal fluid from neurologically normal, elderly subjects using two-dimensional LC-MS/MS. J Proteome Res 2004, 3:97-103.
10. Yuan X, Desiderio DM: Proteomics analysis of human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 815:179-189.
11. Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, Zhou Y, Pan C, Yi E, Eng J, Wang Q, Aebersold RH, Montine TJ: Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 2005, 7:125-133.
12. Grus FH, Podust VN, Bruns K, Lackner K, Fu S, Dalmasso EA, Wirthlin A, Pfeiffer N: SELDI-TOF-MS ProteinChip array profiling of tears from patients with dry eye. Invest Ophthalmol Vis Sci 2005, 46:863-876.
13. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, Farias-Eisner R. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A 2003, 100:12343-12348.
14. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM: Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat 2005, 89:149-157.
15. Petricoin EF, Liotta LA: SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004, 15:24-30.
16. Sauter ER, Shan S, Hewett JE, Speckman P, Du Bois GC: Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int J Cancer 2005, 114:791-796.
17. Schaub S, Rush D, Wilkins J, Gibson IW, Weiler T, Sangster K, Nicolle L, Karpinski M, Jeffery J, Nickerson P: Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 2004, 15:219-227.
18. Merchant M, Weinberger SR: Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000, 21: 1164-1177.
19. Diamandis EP, van der Merwe DE: Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res 2005, 11:963-965.
20. Issaq HJ, Veenstra TD, Conrads TP, Felschow D: The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002, 292:587-592.
21. Pusch W, Flocco MT, Leung SM, Thiele H, Kostrzewa M: spectrometry-based clinical proteomics. Pharmacogenomics 2003, 4:463-476.
22. Brouwers FM, Petricoin EFIII, Ksinantova L, Breza J, Rajapakse V, Ross S, Johann D, Mannelli M, Shulkin BL, Kvetnansky R, Eisenhofer G, Walther MM, Hitt BA, Conrads TP, Veenstra. TD, Mannion DP, Wall MR, Wolfe GM, Fusaro VA, Liotta LA, Pacak K: Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocr Relat Cancer 2005, 12:263-272.
23. Rai AJ, Zhang Z, Rosenzweig J, Shih I, Pham T, Fung ET, Sokoll LJ, Chan DW: Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002, 126:1518-1526.
24. Schaub S, Wilkins JA, Antonovici M, Krokhin O, Weiler T, Rush D, Nickerson P: Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am J Transplant 2005, 5:729-738.
25. Wulfkuhle JD, Liotta LA, Petricoin EF: Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003, 3:267-275.
26. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD: Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003, 2:1096-1103.
27. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, Tempst P: Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 2004, 76:1560-1570.
28. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser DF, Sanchez JC: A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003, 3:1486-1494.
29. Gineste C, Ho L, Pompl P, Bianchi M, Pasinetti GM: High-throughput proteomics and protein biomarker discovery in an experimental model of inflammatory hyperalgesia: effects of nimesulide. Drugs 2003:23-29.
30. Sanchez JC, Guillaume E, Lescuyer P, Allard L, Carrette O, Scherl A, Burgess J, Corthals GL, Burkhard PR, Hochstrasser DF: Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2004, 4:2229-2233.
31. Mannes AJ, Martin BM, Yang HT, Keller JM, Lewin S, Gaiser RR, Iadarola MJ: Cystatin C as a cerebrospinal fluid biomarker for pain in humans. Pain 2003, 102:251-256.
32. Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L, Newhall K, Cudkowicz ME, Brown RH Jr, Bowser R: Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. journal of Neurochemistry 2005, 95:1461-1471.
33. Ruetschi U, Zetterberg H, Podust VN, Gottfries J, Li S, Simonsen AH, McGuire J, Karlsson M, Rymo L, Davies H, Minthon L, Blennow K: Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Experimental Neurology 2005, 196:273-281.
34. Hansson SF, Puchades M, Blennow K, Sjogren M, Davidsson P: Validation of a prefractionation method followed by two-dimensional electrophoresis - Applied to cerebrospinal fluid proteins from frontotemporal dementia patients. Proteome Sci 2004, 2:7-11.
35. Maccarrone G, Milfay D, Birg I, Rosenhagen M, Holsboer F, Grimm R, Bailey J, Zolotarjova N, Turck CW: Mining the human cerebrospinal fluid proteonne by immunodepletion and shotgun mass spectrometry. Electrophoresis 2004, 25:2402-2412.
36. Maccarrone G, Birg I, Malisch E, Rosenhagen MC, Ditzen C, Chakel JA, Mandel F, Reimann A. Doertdudak CC, Haegler K, Holsboer F, Turck CW: In-depth analysis of the human CSF proteome using protein prefractionation. Clinical Proteomics Journal 2004, 1:333-364.
37. Righetti PG, Castagna A, Antonucci F, Piubelli C, Cecconi D, Campostrini N, Rustichelli C, Antonioli P, Zanusso G, Monaco S, Lomas LBoschetti E: Proteome analysis in the clinical chemistry laboratory: myth or reality? Clin Chim Acta 2005, 357:123-139.
38. Righetti PG, Castagna A, Antonioli P, Boschetti E: Prefractionation techniques in proteome analysis: the mining tools of the third millennium. Electrophoresis 2005, 26:297-319.
39. Mehta Al, Ross S, Lowenthal MS, Fusaro V, Fishman DA, Petricoin EFIII, Liotta LA: Biomarker amplification by serum carrier protein binding. Dis Markers 2003, 19: 1-10.
40. Zhou M, Lucas DA, Chan KC, Issaq HJ, Petricoin EF III, Liotta LA, Veenstra TD, Conrads TP: An investigation into the human serum "interactome". Electrophoresis 2004, 25:1289-1298.